| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Treatment with gliadin p31-43 (100 μg/mL; 30 minutes–6 hours) causes the MyD88/TLR7 complexes and triggers downstream signaling through the activation of p38, ERK, JNK, and MAPKs. pY-ERK, JNK (pY-JNK), and p38 (pY-p38) are all found at higher levels when gliadin p31–43 is present[1]. When CaCo-2 cells are treated with gliadin p31-43, their NF-κB phosphorylation rises from 0.45 in control cells to 0.86. causes the MxA protein to significantly increase in expression. Following treatment with Gliadin p31-43, the levels of IFN-α 7 and 17 mRNAs are also examined[1]. Gliadin p31–43 occludes vesicular trafficking in CaCo-2 cells by localizing to the early endosomes. The growth factor-regulated tyrosine kinase substrate (HRS) is incorrectly localized to early endosomes when gliadin p31–43 is present, which delays the formation of endocytic vesicles[1].
|
|---|---|
| ln Vivo |
Apoptosis-associated speck-like (ASC) complex activation is caused by gliadin p31-43 (10 μg) intraluminally injected, which demonstrates a sequence-specific spontaneous ability to form structured oligomers and aggregates in vitro[2]. The increase in IL-1β shows that oral administration of Gliadin p31-43 (20 μg) to wild type C57Bl/6 mice activates the inflammasome caspase-1 pathway in the small intestine mucosa. The natural tendency of gliadin p31–43 to form oligomers is what initiates the NLRP3 inflammasome[2].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: CaCo -2 cells Tested Concentrations: 100 μg/mL Incubation Duration: 30 minutes, 3 hrs (hours), 6 hrs (hours) Experimental Results: demonstrated the increase in formation of the MyD88/TLR7 complex, and increased in the level of TLR7. |
| References |
[1]. Merlin Nanayakkara, et al. P31-43, an undigested gliadin peptide, mimics and enhances the innate immune response to viruses and interferes with endocytic trafficking: a role in celiac disease. Sci Rep. 2018 Jul 17;8(1):10821.
[2]. María Florencia Gómez Castro, et al. p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1- Dependent Mucosal Damage in Small Intestine. Front Immunol. 2019 Jan 30;10:31. |
| Molecular Formula |
C71H102N18O20
|
|---|---|
| Molecular Weight |
1527.68
|
| Exact Mass |
1526.751
|
| CAS # |
176326-01-5
|
| Related CAS # |
Gliadin p31-43 TFA
|
| PubChem CID |
102122813
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-6.9
|
| Hydrogen Bond Donor Count |
16
|
| Hydrogen Bond Acceptor Count |
21
|
| Rotatable Bond Count |
42
|
| Heavy Atom Count |
109
|
| Complexity |
3310
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CC(C)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N3CCC[C@H]3C(=O)N4CCC[C@H]4C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)O)N
|
| InChi Key |
RCFWLPRMZAFVQJ-PEWBXTNBSA-N
|
| InChi Code |
InChI=1S/C71H102N18O20/c1-38(2)34-42(72)60(97)78-37-59(96)79-43(20-25-54(73)91)61(98)80-44(21-26-55(74)92)62(99)82-46(23-28-57(76)94)67(104)86-30-6-12-50(86)65(102)84-48(35-39-10-4-3-5-11-39)69(106)89-33-9-15-53(89)70(107)88-32-8-14-52(88)64(101)81-45(22-27-56(75)93)63(100)83-47(24-29-58(77)95)68(105)87-31-7-13-51(87)66(103)85-49(71(108)109)36-40-16-18-41(90)19-17-40/h3-5,10-11,16-19,38,42-53,90H,6-9,12-15,20-37,72H2,1-2H3,(H2,73,91)(H2,74,92)(H2,75,93)(H2,76,94)(H2,77,95)(H,78,97)(H,79,96)(H,80,98)(H,81,101)(H,82,99)(H,83,100)(H,84,102)(H,85,103)(H,108,109)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 50 mg/mL (32.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (65.46 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.6546 mL | 3.2729 mL | 6.5459 mL | |
| 5 mM | 0.1309 mL | 0.6546 mL | 1.3092 mL | |
| 10 mM | 0.0655 mL | 0.3273 mL | 0.6546 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
